EAM
ACRS icon

Eventide Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Eventide Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-140,000
Closed -$2.45M – 145
2018
Q1 		$2.45M Hold
140,000
– – 0.11% 108
2017
Q4 		$3.45M Hold
140,000
– – 0.18% 91
2017
Q3 		$3.61M Hold
140,000
– – 0.2% 85
2017
Q2 		$3.8M Hold
140,000
– – 0.24% 80
2017
Q1 		$4.17M Sell
140,000
-80,000
-36% -$2.31M 0.28% 76
2016
Q4 		$5.97M Buy
220,000
+80,000
+57% +$2.04M 0.39% 65
2016
Q3 		$3.58M Buy
+140,000
New +$2.97M 0.22% 79

Other funds holding ACRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Eventide Asset Management's ACRS Position: Q2 2018 in Review

Eventide Asset Management sold out of Aclaris Therapeutics (ACRS) in Q2 2018, closing a stake of 140,000 shares — an estimated $2.45M sold.

Eventide Asset Management first reported a position in ACRS in Q3 2016 and held it in 7 quarters. The position peaked at $5.97M in Q4 2016. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2018.

  • Eventide Asset Management reported no remaining Aclaris Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Eventide Asset Management sold 140,000 Aclaris Therapeutics shares in Q2 2018, an estimated $2.45M.
  • Eventide Asset Management first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 7 quarters.
  • Eventide Asset Management's Aclaris Therapeutics position peaked at $5.97M in Q4 2016.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2018.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.